Moderna, Inc. (MRNA) compared with its closest peers (RVMD, BIIB, NBIX, EXEL, HALO). Peer set by Business model: Biotech (Clinical / Commercial-Stage) + Big Pharma / Branded Drugs; 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Revolution Medicines, Inc. (RVMD) | $45.02B | -13.4 |
| Biogen Inc. (BIIB) | $31.69B | 23.1 |
| Neurocrine Biosciences, Inc. (NBIX) | $15.54B | 22.0 |
| Exelixis, Inc. (EXEL) | $13.30B | 15.5 |
| Halozyme Therapeutics, Inc. (HALO) | $12.05B | 29.1 |
| Apogee Therapeutics, Inc. (APGE) | $10.15B | -17.9 |
| Kymera Therapeutics, Inc. (KYMR) | $10.10B | -21.1 |
| Krystal Biotech, Inc. (KRYS) | $9.97B | 40.5 |
| Immunovant, Inc. (IMVT) | $9.16B | -9.0 |
| Vaxcyte, Inc. (PCVX) | $8.86B | -8.2 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
MRNA overview · MRNA earnings · MRNA financials · MRNA KPIs · MRNA investor relations · MRNA ownership · MRNA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.